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Critical carePurpose: Thiazides are suggested as a treatment for intensive care unit (ICU)–acquired hypernatremia (IAH). The
primary aim of the study was reducing serum sodium concentration (sNa) in patients with IAH with hydrochlo-
rothiazide (HCT) in comparison to placebo. Secondary end points were a difference in urine sodium concentra-
tion (uNa) and duration of severe IAH.
Materials:Amonocentric, double-blind, placebo-controlled trial was conducted in 50 patientswith IAH and urine
potassium+ uNa less than sNa in a spot urine sample. Patients were randomized to HCT 25 mg or placebo 1 qd
for maximal 7 days. Patients on renal replacement therapy, on medication inducing diabetes insipidus, or with
recent use of diuretics were excluded. IAH was deﬁned as sNa of at least 143 mmol/L.
Results: At baseline, sNa and uNa were comparable between groups. During the study period, sNa decreased sig-
niﬁcantly withmedian 4mmol/L in both groups, with no signiﬁcant difference between groups (P= .32). Medi-
an uNa increased signiﬁcantly in both groups (46 [16-86] mmol/L in the HCT-group; 20 [10-66]mmol/L in the
placebo group), with no difference between groups (P = .34). Median duration of sNa of at least 145 mmol/L
was 3 days in both groups (P= .91).
Conclusion: HCT 25 mg 1 qd did not signiﬁcantly affect sNa or uNa in patients with IAH.






Intensive care unit (ICU)–acquired hypernatremia (IAH) is a com-
mon ﬁnding with a reported incidence between 3% and 17% [1-8]. IAH
has clinical signiﬁcance because it is associated with prolonged length
of stay in the ICU and higher morbidity and mortality [6-8]. IAH is sup-
posed to stem mainly from disturbances in water and sodium homeo-
stasis, including salt overloading and inadequate water administration
[9-15]. As such, the traditional approach to reduce serum sodium con-
centration (sNa) in hypernatremic ICU patients is to reduce sodium in-
take and enhance (par)enteral water administration. Although this
strategy is effective to some extent, it is of note that a systematic reduc-
tion in parenteral sodium intake was not associated with a reduction in
incidence of IAH [2]. Moreover, water suppletion reduces sNa but does
not interfere with potential other underlying mechanisms.ts of interest.





. This is an open access article underImpairment in renal excretion of cationswas identiﬁed as one of the
contributing factors leading to IAH [15]. To enhance sodium excretion,
treatment with hydrochlorothiazide (HCT) has been suggested [9,15].
The expected rise in sodium excretion is due to inhibition of sodium re-
absorption in the distal tubule and reduced free water clearance [16].
However, data on the effectiveness of HCT in the speciﬁc setting of
IAH seem to be missing. To evaluate the effect of HCT treatment on
sNa in IAH, a prospective, randomized, placebo-controlled clinical trial
was conducted.
2. Materials and methods
2.1. Design and setting
This single-center, prospective, double-blind, randomized, placebo-
controlled trial was conducted in a 20-bed mixed medical and surgical
ICU in a tertiary teaching hospital. The primary aim of the study
was to detect in patients with IAH a difference in reduction of sNa of
at least 3 mmol/L after treatment with HCT in comparison to placebo.
Secondary end points were the difference in renal sodium excretion,
the duration of sNa of at least 145mmol/L, and fractional sodium excre-
tion (FEna).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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This trial consisted of 2 study arms. HCT (25mg) or placebowas admin-
istered once daily via a nasogastric tube. HCT is not labeled for the use of
lowering sNa, but hyponatremia is a well-known adverse effect of this
drug. Patientswere randomizedby a list, generated by a dedicatedphar-
maceutical trial assistant, in blocks of 6 patients each to distribute pa-
tients on HCT or placebo equally during the study period. This
randomization list was only available to the pharmaceutical staff re-
sponsible for the preparation of the study medication. Criteria for inclu-
sion and exclusion are presented in Table 1. In this study, IAH was
deﬁned as a sNa of at least 143mmol/L. This cutoff valuewas chosen be-
cause of the association with inverse outcome of even mild IAH as ob-
served by Darmon et al [7]. The outcome “prevalence of more severe
IAH (sNa ≥ 145mmol/L)”was added to investigate if HCT could be ben-
eﬁcial in preventing IAH from becoming more severe compared with
placebo. Patients were screened for their eligibility to be enrolled in
the study by spot urine samples. Patients were considered eligible in
case urine sodiumconcentration (uNa) plus urine potassium concentra-
tion did not exceed sNa. Informed consent was obtained from the pa-
tient or next of kin in compliance with applicable laws. The study
protocol was approved by the local ethic board and registered at
clinicaltrials.gov (NTC01974739) and Eudract (2013-002165-19).2.2. Data collection
Collected baseline parameters included demographic data, diagnosis
and severity of illness on admission, serum electrolyte concentrations,
and data concerning renal excretion. Study medication was adminis-
tered at 6:00 PM, after which collection of 24-hour urine started for the
duration of the study period. During the study period, electrolytes
were measured routinely 4 times a day by point-of-care testing
(ABL800 AutoCheck; Radiometer Paciﬁc Pty Ltd, Australia and New
Zealand). Serum creatinine and urea concentrations were routinely
measured once daily. FEna was calculated according to Eq. (1). In addi-
tion, collected data included ﬂuid balances, dose and kind of adminis-
tered diuretics, gastric retentions, and severity of illness. All patients
with gastric retention greater than 150 mL per 6 hours over a period
of more than 24 hours were equipped with a duodenal feeding tube.
By protocol, administration of study medication was limited to a maxi-
mum of 7 days. Other reasons to end the administration of study med-
ication were a sNa less than 139 mmol/L, the need for (unanticipated)
renal replacement therapy, administration of more than 120mg furose-
mide per day, and ICU discharge. A certain administered dose of furose-
mide was allowed to investigate the effect of HCT on IAH in common
daily ICU practice. In this daily practice, prescription of other diuretics
is very rare. In case sNa exceeded 149mmol/L, glucose 5%was adminis-
tered intravenously until sNa returned to less than or equal to 149
mmol/L. Hypokalemia (b3.5 mmol/L) was corrected by a nurse-driven
potassium suppletion protocol. All clinical data were automatically
stored in a patient data management system fromwhich they were ex-
tracted into an anonymized database. No funding was received.Table 1
Inclusion and exclusion criteria
Inclusion
ICU-acquired serum sodium concentration ≥ 143 mmol/L
Expected ICU stay N24 h
18 y of age or above
Indication of incapacity for renal sodium
excretion: urine sodium+ urine
potassium b serum sodium concentration
Informed consent2.3. Statistical analysis
The power analysis was based on data previously collected in pa-
tients with sNa of at least 143 mmol/L in our ICU. Main goal was to de-
tect a difference of 3 mmol/L in reduction in sNa between both groups
with a power of 80% and α of 5%. Including correction for 2 dropouts
per group, 25 patients were needed in both groups. Data were collected
and analyzed in SPSS versions 19 and 20 (IBM, Armonk, NY) based on an
intention-to-treat principle. Because the majority of variables was not
normally distributed, data are expressed as median (interquartile
range [IQR]). Analyses were conducted using Mann-Whitney U testing
for independent variables,Wilcoxon signed rank test for dependent var-
iables, and Fisher exact test to compare percentages. Outcomes were
considered signiﬁcant at P ≤ .05. Effect sizes were calculated according
to Eq. (2).
Eq. (1): Fractional sodium excretion:





where FEna is fractional sodium excretion, uNa is urine sodium ex-
cretion inmmol/L, sNa is serumsodium concentration inmmol/L, sCreat
is serum creatinine concentration in μmol/L, and uCreat is urine creati-
nine concentration in mmol/L.






where Z= Z-score and n= number of observations
3. Results
3.1. Baseline characteristics
In the inclusion period, 2321 patients were admitted, of which
299 patients developed IAH (Fig. 1). Urine screening was performed
in 116 patients. Main reason not to perform a screening spot urine
sample was an expected length of stay in the ICU of less than 24
hours. Baseline characteristics did not differ signiﬁcantly between
groups (Table 2). In both groups, the study was terminated prema-
turely in 1 patient: 1 patient because of hypercalcemia, which was
considered a contraindication of HCT, and the other because of the
development of diabetes insipidus. Serum creatinine according to
laboratory reference values for men and women was elevated in 13
patients in the HCT group and 8 patients in the placebo group (P =
.25) [17].
3.2. Primary and secondary end points
Main results are shown in Tables 3 and 4 and Figs. 2 and 3. On the
last day of the study,median sNawas 141 (137-147)mmol/L in patients
treated with HCT and 144 (139-146) mmol/L in patients treated withExclusion
Serum sodium concentration on ICU admission ≥143 mmol/L
Central or nephrogenic diabetes insipidus
Severe hypokalemia
Administration of lithium, amphotericin B, or agents affecting vasopressin receptors
(Anticipation of) renal replacement therapy
Diuresis b400 mL/d
Use of HCT b48 h previous to urine screen
Use of loop diuretics b12 h previous to urine screen
Intolerance to thiazides
Pregnancy
Fig. 1. Flow diagram study enrolment. uK indicates urine potassium concentration in mmol/L; CVVH, continuous venovenous hemoﬁltration.
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niﬁcantly over time by 4 mmol/L in both groups (P b .01). However, the
decrease in sNa over time, which was the primary end point, was not
different between groups (P = .47). If groups were divided into quar-
tiles based on their sNa at study start (b144, 144-145, 146-147, or
N147 mmol/L), still no differences in decrease of sNa occur. Median
uNa at the end of the study was 110 (70-124) mmol/L in the HCT
group and 84 (52-126) mmol/L in the placebo group (P= .40). In com-
parison to baseline, median uNa increased signiﬁcantly over time by 46
(26-86) mmol/L in patients treated with HCT and 36 (9-78) mmol/L in
patients on placebo (P b .01). However, this increase did not differ be-
tween groups (P= .70). Median duration of sNa of at least 145 mmol/L
was 3 days in both groups (P= .91).Median FEna at baseline was 0.44% (0.17%-1.09%) in the HCT group
and 0.36% (0.19%-0.89%) in the placebo group (P= .69). At the end of
the study, median FEna was 1.23% (0.62%-2.12%) in the HCT group and
0.89% (0.44%-1.28%) in the placebo group (P = .09). Median increase
in FEna over time was 0.96% (0.14%-1.47%) in the HCT group, which is
a relative increase of 257% (27%-487%). This increase in the placebo
group was 0.40% (−0.01% to 0.90%), which is a relative increase of
125% (−2% to 298%) (P b .01). However, there was no signiﬁcant differ-
ence in both absolute (P= .53) and relative (P= .19) increase in FEna
between groups. Effect sizes of both HCT and placebo on decrease of
sNa and increase of uNa and FEna did not exceed 0.5. Median serum glu-
cose concentrations were onmost study days between 7 and 7.5mmol/
L and did not differ between groups.
Table 2
Baseline characteristics
Variables HCT (n = 25) Placebo (n = 25) P-value
Age, years 65 [58–71] 67 [57–77] 0.58
Male, n (%) 21 (84) 15 (60) 0.06
BMI 27.3 [25–31.2] 27.6 [22.4–34.4] 0.99
Reason for ICU-admission, n (%)
(Complications after) cardiothoracic surgery 2 (8) 5 (20) 9>>=
>>;
0.20
Post resuscitation 2 (8) 3 (12)
Sepsis 6 (24) 10 (40)
Respiratory failure 8 (32) 5 (20)
Miscellaneous 7 (28) 2 (8)
APACHE IV-score on admission 93 [73–119] 78 [67–99] 0.07
SOFA-score on admission 8 [8–11] 8 [5–11] 0.20
SOFA-score on study start 6 [4–9] 5 [3–7] 0.10
Days until study inclusion 5 [3–7] 8 [5–15] 0.14
Serum [Na+] on admission, mmol/l 138 [134–139] 138 [136–141] 0.40
Serum [Na+] on study start, mmol/l 146 [145–148] 146 [144–150] 0.96
Serum [creat] on study start, μmol/L 84 [72–148] 81 [69–108] 0.10
Serum [urea] on study start, mmol/l 14 [9–23] 13 [10–16] 0.14
Urine osmolality on study start, mosm/kg 613 [473–804] 570 [506–710] 0.68
Urine [Na+] in screening sample, mmol/l 25 [10–62] 20 [10–66] 0.80
Urine [K+] in screening sample, mmol/l 40 [29–49] 36 [28–50] 0.89
Urine [Na+] on study start, mmol/l 48 [23–80] 39 [21–82] 0.60
Fluid balance on study start, L 2.3 [−1.2–7.1] 1.1 [−2.2–4] 0.16
Duration of study, days 7 [4–7] 6 [4–7] 0.64
Total ICU length of stay, days 21 [13–30] 24 [14–35] 0.53
228 M.M.C.O. van IJzendoorn et al. / Journal of Critical Care 38 (2017) 225–230No adverse effects of study medication were reported. During or
shortly after the study period, 4 patients died, of which 3 were in the
placebo group. All cases were reported to the local ethical board, who
decided that it was most unlikely that these deaths were related to
the study protocol.
4. Discussion
In this study, patients treated with 25 mg HCT once daily did not
show a difference in the reduction of sNa comparedwith patients treat-
ed with placebo. In addition, no signiﬁcant differences in renal sodium
excretion, the duration of sNa of at least 145mmol/L, and FEna were ob-
served. However, in both groups, sNa decreased and uNa increased
compared with baseline.
These results do not seem to be in line with previous literature in
which thiazides are suggested as treatment for IAH [9,15]. However,
the recommendation to use thiazides for IAH do not seem to be based
on solid data in the speciﬁc ICU setting. In general, such recommenda-
tions are based upon the presumed mechanisms of action and extrapo-
lated from non-ICU patient populations. Indeed, in our study, a low
renal cation excretion was found in 86% of all patients with IAH,Table 3
Main study results at last day of study inclusion
Variables HCT (n = 25) Placebo (n = 25) P value
Decrease in serum [Na+], mmol⁎ 4 (1-9) 4 (2-6) .47
Serum [Na+], mmol/L 141 (137-147) 144 (139-146) .32
Increase in urine [Na+], mmol 46 (26-86) 36 (9-78) .31
Urine [Na+], mmol/L 110 (70-124) 84 (52-126) .34
Serum [creat], μmol/L 76 (46-147) 68 (58-83) .49
Serum [urea], mmol/L 13 (8-21) 11 (8-12) .27
Fluid balance at last day of study, L −1.3 (−5.2 to 3.7) −1.4 (−6.2 to 2.9) .65
Mean dose of loop diuretics per
study day, n, mg 13, 3 (0-13) 15, 6 (0-16) .45
Data are expressed as median (IQR) unless stated otherwise. P value b .05 is considered as
statistically signiﬁcant. Fluid balance corrected for insensible loss of 500 mL/d since ICU
admission. Dose of loop diuretics: total amount of administered furosemide during
study period/days of inclusion.
⁎ Primary end point.whereas ﬂuid balances were positive. This suggests a potential role of
abnormal cation handling by the kidney in critically ill patients in the
development of IAH. The question is why we did not observe a sodi-
um-lowering effect of thiazides in our study. This effect was expected
because of both the pharmacodynamics of thiazides and the various
publications describing thiazide-induced hyponatremia in non-ICU pa-
tients [18-32].
When analyzing this discrepancy, several factors have to be taken
into account. Firstly, the mechanisms of action of HCT could be altered
in critically ill patients. HCT belongs to the group of thiazides. These
drugs increase renal sodium and chloride excretion by blocking the
sodium-chloride cotransporter (SCC), thereby interfering with reab-
sorption of these ions. The main site of action is the distal tubule
[16,18,22,33]. Under normal circumstances, only 5% of ﬁltrated sodium
is reabsorbed in the distal tubule against 70% in the proximal tubule and
20% to 25% in Henle's loop. Nevertheless, blocking sodium reabsorption
in the distal tubule is potentially effective because less compensating
mechanisms to undo this effect are present [16]. However, our study
populationwas characterized by a high incidence of acute kidney injury
(AKI). Thirteen of 25 patients on HCT had elevated serum creatinine
values after the initial ﬂuid resuscitation, whereas serum creatinine
even underestimates the incidence of AKI [34]. Reduction of glomerular
ﬁltration rate is a hallmark of AKI [35]. As a consequence, the absolute
sodium content per time in the distal tubule may be diminished,
conceivably interfering with the net effect of sodium reabsorption
blocking agents.
Factors inﬂuencing thiazides-induced reduction in sNa are exten-
sively described in light of thiazide-induced hyponatremia and includeTable 4
Decrease in serumsodiumconcentration comparedwith baseline, divided on serum initial
sodium concentration
sNa at study start HCT (n = 25) Placebo (n = 25) P value
b144 mmol/L, n 4.5 (0.75–9.25), 6 3 (2.25–6.75), 4 .76
144-145 mmol/L, n 4 (0–9), 11 5 (0.5–7), 9 .82
146-147 mmol/L, n 8 (1–11), 5 4 (1–5), 7 .11
N147 mmol/L, n 2 (1-.), 3 5 (1–6), 5 1
Fig. 2. Decrease in serum sodium concentration and increase in urine sodium
concentration compared with baseline. *Primary end point.
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mone (ADH) activity [20,23-27,30,31,36-37]. In the acute phase of crit-
ical illness, ADH activity is enhanced. Apart from blocking the SCC, the
sNa-lowering effect of thiazides may additionally be attributed to a di-
rect effect of thiazide diuretics on the plasma membrane expression of
aquaporin 2 [30]. However, this is associated with water-intake–medi-
ated weight gain, hampered by limited water excess of our patients,
and expressed by the negative ﬂuid balances at the end of the study.
Lastly, thiazide resistance, a compensatory mechanism by blocking
of the thiazide-sensitive SCC, could have played a role [38]. However,
so far, no data on thiazide resistance in relation to critical illness have
been reported.
Our study has several limitations. We restricted our protocol to one
particular thiazide and one speciﬁc dosage regimen of HCT. Based on the
power analysis, our sample sizes were small but appropriate. However,
these samples could have been too small to detect a relatively small dif-
ference in patients with borderline hypernatremia. On the other hand,
the courses of sNa during the entire study duration seem to be similar.
Many types of thiazides were developed differing mainly by their po-
tency, but dose-response curves and chloruretic effects are comparable
[22]. Although higher doses of HCT are considered safe and prescribed
for other indications, no additional effect on electrolyte excretion
could be expected [21]. However, patients with impaired renal function
possibly need a higher dose of HCT to evoke an effect at its site of action
in the kidney. HCT has a half-life of approximately 9 hours, soFig. 3. Course of serum sodium concentration during study period, both groups.administering it twice daily could potentially enhance sodium excretion
[28,32]. In our protocol, duration of treatment was limited to 7 days.
This should be long enough to result in both lowering sNa and enhanc-
ing renal sodium excretion [19,21-23,28,37]. Based on the medication
veriﬁcation system in our patient data management system, only 2 pa-
tients missed 2 doses of medication, concerning 1 patient in both study
groups. Adequate administration of study medication seems likely be-
cause only few patients had gastric retentions, of which all were fed
by duodenal tube. Bypassing the stomach does not inﬂuence absorption
of HCT becausemost resorption takes place in the duodenum and upper
jejunum [19]. Administering HCT in our study was limited to patients
with impaired renal sodium excretion. Therefore, its effect in patients
without impaired renal sodium excretion needs further investigation.
The use of loop diuretics is almost inevitable in the ICU setting and
may interfere with HCT sodium reabsorption [39]. We carefully limited
the use of loop diuretics by protocol, and its use was well balanced be-
tween groups. Finally, it is possible that IAH is not related to sodium in-
take orwater balance, but so far, no data were available to establish this
assumption.
5. Conclusions
In this single-center, randomized, placebo-controlled clinical trial,
we could not identify a signiﬁcant effect of enterally administered HCT
25 mg 1 qd on serum sodium reduction or renal sodium excretion in
critically ill patients with IAH. These results warrant further investiga-
tions to unravel the etiology of impaired renal sodium excretion in
IAH and the potential for therapeutic interventions.
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